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astrocytomas underlies poor predictive accuracy of current histologic grading approaches. To test this
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in an institutional cohort of IDH-mutant astrocytomas. In our cohort, there was no mitotic activity
threshold that was reflective of progression-free or overall survival (OS). Furthermore, in a multivariate
Cox regression model consisting of mitotic activity, molecular markers, and clinical characteristics, only
CDKN2A homozygous deletion was identified as a relevant variant for poor OS. We conclude that lack
of defined mitotic figure thresholds may not contribute to underperformance of histological grading for
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Abstract
Current histological grading recommendations for isocitrate dehy-
drogenase (IDH)-mutant astrocytoma are imprecise and not reliably
predictive of patient outcome, while somatic copy number altera-
tions are emerging as important prognostic biomarkers. One expla-
nation for this relative underperformance of histological grading is
that current criteria to distinguish World Health Organization
(WHO) grade III anaplastic astrocytomas from lower-grade diffuse
astrocytomas (WHO grade II) are vague (“increased mitotic
activity”). This qualitative approach ensures diagnostic uncertainty
and a broad “gray zone” where both diffuse and anaplastic designa-
tions can reasonably be assigned. Thus, we hypothesized that inter-
observer variability and lack of defined mitotic thresholds for IDH-
mutant astrocytomas underlies poor predictive accuracy of current
histologic grading approaches. To test this hypothesis, we quantified
total mitotic figures and maximum mitotic activity per 10 high-
powered fields in an institutional cohort of IDH-mutant astrocyto-
mas. In our cohort, there was no mitotic activity threshold that was
reflective of progression-free or overall survival (OS). Furthermore,
in a multivariate Cox regression model consisting of mitotic activity,
molecular markers, and clinical characteristics, only CDKN2A ho-
mozygous deletion was identified as a relevant variant for poor OS.
We conclude that lack of defined mitotic figure thresholds may not
contribute to underperformance of histological grading for IDH-
mutant astrocytomas.
Key Words: Astrocytoma, Glioma, Histopathology, Isocitrate de-
hydrogenase (IDH), Mitosis.
INTRODUCTION
The World Health Organization (WHO) introduced a
classification system of diffuse gliomas in 2016 that integrates
traditional histopathological features with specific molecular
alterations to define “integrated” diagnostic entities (1). The
molecular drivers of this diffuse glioma classification system
is driven broadly by point mutations in exon 4 of isocitrate de-
hydrogenase 1/2 (IDH1/2) and codeletion of whole chromo-
some arms 1p and 19q. Integrating these 2 molecular
alterations into the historical classification system of diffuse
glioma has yielded a better and more reproducible predictor of
clinical outcome than traditional histopathology alone (1, 2).
Although this integrated classification system has much im-
proved reproducibility and concurrence across diagnosticians,
identifying tumors with aggressive or malignant potential in
the context of IDH-mutational status remains challenging, es-
pecially for IDH-mutant astrocytic gliomas. This histopatho-
logical grading scheme for differentiating diffuse astrocytoma
(WHO grade II) from anaplastic astrocytoma (WHO grade III)
(“increased mitotic activity”) was not updated with the inte-
grated classification system, and does not take into account
IDH-mutational status.
For IDH-mutant astrocytic gliomas, differentiation be-
tween diffuse astrocytoma (WHO grade II) and anaplastic as-
trocytoma (WHO grade III) based on histological features
appears to have limited, if any, utility in discriminating out-
comes amongst these tumors (3–5). The historical utility of
the current histologic grading approach is most likely due to
the inclusion of poorly surviving IDH-wildtype astrocytomas
that tended to have higher histological grade. With the new in-
tegrated approach, IDH-mutational status provides effective
differentiation of generally more (IDH-wildtype) or less
(IDH-mutant) aggressive astrocytomas, with a broad range in
each group in which histological grading may provide
additional predictive value. However, there are currently no
diagnostic criteria that specifically separate IDH-mutant or
IDH-wildtype tumors into subgroups with predicted survival,
and broadly applied criteria are generally not helpful.
In comparison to histological features, there are emerg-
ing studies demonstrating the utility of certain molecular
markers reflective of aggressive behavior within IDH-mutant
astrocytomas. Our group (5, 6), and others (7–9), have demon-
strated that a handful of molecular somatic copy number
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alterations (SCNAs) portend survival within IDH-mutant as-
trocytic gliomas. These SCNAs include CDKN2A deletion (5,
6, 8, 10), total copy number load (8, 11), chromosome 12p
gain/CDK4 amplification (6, 9, 10), and loss of chromosome
14 (5, 6, 9). However, these SCNAs, or other molecular
markers, are not widely available for diagnostic neuropathol-
ogy practice, so there is still a pressing need for a predictive
histologic variable beyond “increased mitotic activity” for
grading for IDH-mutant astrocytomas.
As has been shown in some other tumor types (4, 12–
15), a rational and practical mitotic index threshold for grading
IDH-mutant astrocytomas could be effective for patient risk-
stratification. Clear mitotic index cutoffs for predicting sur-
vival for IDH-mutant astrocytomas would guide reproducible
histological grading and improve diagnostic practice and thus
patient care, especially in resource-limited environments. Fur-
thermore, clear histological guidelines could help to reduce as-
trocytoma grading variability among pathologists (16). We
hypothesized that quantitative thresholds for mitotic activity
would improve predictive accuracy and could therefore be
useful for histopathological grading of IDH-mutant astrocyto-
mas. To test this hypothesis, we reviewed a consecutive insti-
tutional cohort of newly diagnosed resected IDH-mutant
astrocytomas and systematically evaluated various quantita-
tive mitotic indices to determine if specific thresholds could
predict clinical outcome, and thus help to establish concrete




The use of human subject material was performed in ac-
cordance with the World Medical Association Declaration of
Helsinki and with the approval of the University of Washing-
ton Institutional Review Board. Institutional records were que-
ried to identify newly diagnosed WHO grade II and III diffuse
gliomas occurring between 2000 and 2010 as previously de-
scribed (5). Chart review was performed to ascertain extent of
clinical follow up and additional clinical characteristics. Cases
included in the study had clinical follow up of at least 5 years,
or recurrence or death if sooner. The diagnosis of a WHO
grade II or III diffuse glioma was confirmed by slide review of
a board-certified neuropathologist (P.J.C.). Cases with addi-
tional tissue material available underwent molecular analysis
for classification according to current WHO guidelines.
Diffuse Glioma Classification
DNA was extracted from formalin-fixed paraffin-em-
bedded (FFPE) tissue blocks using the QIAamp DNA FFPE
Tissue Kit (Qiagen Inc., Germantown, MD) and underwent
Qubit fluorometric quantitation (Invitrogen, Carlsbad, CA).
Each tissue block tested had tumor representing at least 70%
of the tissue present. Quality control of the DNA was per-
formed using the Infinium FFPE QC Kit (Illumina, San Diego,
CA) according to the manufacturer’s protocol. Bisulfate con-
version of the DNA using the EZ-DNA Methylation Kit
(Zymo Research, Irvine, CA) was followed by use of the
FFPE Restoration Kit (Illumina) according to the manufac-
turer’s protocol and included the Illumina “Alternative Incuba-
tion Conditions” modification to the conversion protocol. The
DNA was then processed for genome-wide methylation analy-
sis using the InfiniumR EPIC Methylation Array (Illumina).
IDAT files were uploaded to the dkfz molecular neuropathol-
ogy website (https://www.molecularneuropathology.org) and
analyzed (classifier v11b4 version 2.0) to classify diffuse glio-
mas into 1 of the 3 following categories: Astrocytoma IDH-
wildtype, astrocytoma IDH-mutant, and oligodendroglioma
IDH-mutant and 1p/19q-codeleted (17). Additionally, this
analysis was used to determine methylation status for the O-6-
methylguanine-DNA methyltransferase (MGMT) promoter.
Histological Slide Review
Routine diagnostic hematoxylin and eosin (H&E)-
stained slides for each molecularly classified IDH-mutant as-
trocytoma (n¼ 34) were reviewed for mitotic figures indepen-
dently by either RAY, TM, or LL. All tissue on every slide for
each resection specimen was scanned with a 40 objective to
quantify total mitotic counts (upper threshold cap of >20 mi-
toses per specimen) and maximum mitoses per 10 consecutive
high-power fields (HPF). A single HPF is defined in this study
of having a field diameter of 0.55mm and an area of
0.24mm2. The upper limit cap for total mitotic figures was the
point where reviewers ceased counting mitotic figures per
specimen. For slide review, there was no upper limit cap for
counting mitoses per 10 HPF. Reviewers were blinded to the
original neuropathological diagnosis. At least 2 reviewers in-
dependently assessed all slides of 9 of 34 (26.5%) astrocyto-
mas (Supplementary Data Table S1) to determine
interobserver reliability.
Statistics
Interreviewer agreement for mitotic thresholds was
calculated to determine Cohen’s kappa coefficient (18, 19)
for 3 separate threshold tiers: Total mitotic figures (<20 vs
20), maximum mitotic figures per 10 HPF (<3 vs 3),
and maximum mitotic figures per 10 HPF (<6 vs 6).
Cohen’s kappa coefficient determination and Kaplan-Meier
analysis for progression-free and overall survival (OS) were
performed using GraphPad Prism software (Version 7.02,
https://www.graphpad.com/scientific-software/prism). P val-
ues were determined by Cox proportional hazards regres-
sion. Time-dependent receiver operating characteristic
(ROC) estimation for censored survival data was performed
using R software (Version 3.4.4, RProject for Statistical
Computing, http://www.r-project.org/) with the
“survivalROC” package (https://cran.r-project.org/packag-
e¼survivalROC); median survival times used as cutoffs.
Multivariate Cox proportional hazards models with indicated
variables were applied utilizing SPSS statistical software
Version 25.0 (IBM, Armonk, NY).
RESULTS
Review of our institutional files initially identified
178 cases of newly diagnosed adult WHO grade II and III






















































































diffuse gliomas that were resected between the years 2000
and 2010. Of these 178 patients, 109 had documented clini-
cal follow up of at least 5 years, if not recurrence before
this time point. Pathology slides from these 109 patients
were rereviewed to confirm the diagnosis of a WHO grade
II or III diffuse glioma. Tissue blocks with sufficient mate-
rial for molecular characterization existed for 95 of these
cases. DNA was extracted from these tissue blocks, tested
for DNA quality, and underwent whole-genome methylation
analysis for glioma classification according to the 2016
WHO guidelines (1). A total of 66 WHO grade II and III
diffuse gliomas had DNA that passed quality control and
were successfully classified into the following 3 major inte-
grated categories: Astrocytoma IDH-wildtype, WHO grade
II/III (n¼ 7); astrocytoma IDH-mutant, WHO grade II/III
(n¼ 34); and oligodendroglioma IDH-mutant and 1p19q-
codeleted, WHO grade II/III (n¼ 25). Similar to other stud-
ies of WHO grade II and III diffuse gliomas (2, 20–22),
IDH-wildtype astrocytomas had the worse prognosis (me-
dian progression-free survival¼ 532 days, median
OS¼ 956 days), which was followed by IDH-mutant astro-
cytomas (median progression-free survival¼ 2261 days, me-
dian OS¼ undefined) (Fig. 1). The best prognosis was
observed in oligodendroglioma IDH-mutant and 1p/19q-
codeleted (median progression-free survival¼ 3073days,
median OS¼ undefined).
We chose to evaluate quantitative mitotic thresholds in
relation to clinical outcome in the IDH-mutant subgroup (me-
dian age 32.5 years, range 22–55 years) to attempt to clarify
the current “gray zone” for histological grading of IDH-
mutant astrocytomas based upon “increased mitotic activity.”
Representative histological features of this cohort of IDH-
mutant astrocytomas are shown in Figure 2. We quantified
all original H&E resection slides for the IDH-mutant astro-
cytomas for mitotic activity, with moderate to very good
interobserver reliability; Cohen’s kappa coefficients: j
¼ 0.546 (moderate agreement for <20 vs 20 total mitotic
figures), j ¼ 1.000 (very good agreement for <3 vs 3
maximum mitotic figures per 10 HPF), j ¼ 0.571 (moderate
agreement for <6 vs 6 maximum mitotic figures per 10
HPF). Total mitotic figures identified per resection specimen
(all slides), with an upper limit of at least 20 mitoses, were not
predictive of clinical outcome for either progression-free sur-
vival (PFS) (p¼ 0.873) or OS (p¼ 0.300) based on Kaplan-
Meier analysis (Fig. 3). Because total mitotic activity may the-
oretically be a function of the size of resection, we accounted
for this by quantifying maximum mitotic figures present per
10 HPF. Aggressive clinical behavior of IDH-mutant astrocy-
tomas was not reflected by maximum mitotic figures (thresh-
olds of 1–6 mitotic figures per 10 HPF) for either PFS (Fig. 4)
or OS (Fig. 5) by Kaplan-Meier analysis. Likewise, ROC
curve analyses for both total mitotic figures per case and maxi-
mum mitotic figures per 10 HPF failed to identify an associa-
tion between mitotic activity and PFS or OS (Fig. 6).
In addition to mitotic index thresholds, we sought to de-
termine molecular and/or clinical features that may be inde-
pendently associated with decreased PFS and OS in this
institutional cohort. In a Cox regression model of inferior PFS
(Table), we identified relevant associations of MGMT pro-
moter methylation status (methylated vs unmethylated:
HR¼ 0.52, 95% CI¼ 0.09–0.69, p¼ 0.007) and chromosome
14 loss (presence vs absence: HR¼ 8.00, 95% CI¼ 1.99–
32.26, p¼ 0.003). There was also a trend toward an associa-
tion with extent of resection (gross total vs subtotal:
HR¼ 0.40, 95% CI¼ 0.15–1.03, p¼ 0.058). No associations
were found for total mitotic figures, CDKN2A homozygous
deletion status, patient age (age <40 vs  40 years), or Kar-
nofsky Performance Score (KPS). Applying a similar Cox re-
gression model to explore predictors of inferior OS, we
identified CDKN2A deletion (homozygous deletion vs no ho-
mozygous deletion: HR¼ 11.76, 95% CI¼ 1.98–71.43,
p¼ 0.007) as the most relevant predictor of outcome (Table).
There was a trend toward inferior outcome utilizing a cut-off
for total mitotic figures (20 vs <20: HR¼ 5.86, 95%
CI¼ 0.92–37.55, p¼ 0.062), whereas no relevant association
with OS was detected forMGMT promoter methylation status,
loss of chromosome 14, patient age (age <40 vs 40 years),
KPS, or extent of resection. In our Cox proportional hazards
FIGURE 1. Kaplan-Meier survival curves for entire cohort of World Health Organization (WHO) grade II and III diffuse gliomas.
(A) Progression-free survival (PFS) and (B) overall survival (OS) for all diffuse gliomas based upon major classification subtypes
(Astro¼ astrocytoma; Oligo¼oligodendroglioma, Mut¼mutant; WT¼wildtype). P values were determined using Cox
proportional hazard regression.






















































































FIGURE 2. Representative histology for our institutional cohort of IDH-mutant astrocytomas. These gliomas are diffusely infiltrative
into the cortex and subcortical white matter, as evidenced by (A) graded hypercellularity and (B) the presence of background
cortical neurons (original magnification, 200 and 600, respectively). (C) There are intra and intertumoral regions or variably
increased relative hypercellularity (200 original magnification). The neoplastic astrocytic cells appear predominantly as having (D)
fibrillary and/or (E) gemistocytic cytomorphologies (original magnification, 600). (F) Mitotic figures (arrowhead) are variably
present (600 original magnification). Immunohistochemistry shows that neoplastic cells generally have cytoplasmic reactivity for
(G) GFAP and (H) IDH1-R132H mutation, as well as increased nuclear (I) p53 staining (original magnification, 200).
FIGURE 3. Kaplan-Meier survival curves for IDH-mutant astrocytomas stratified total counted mitotic figures. (A) Progression-
free survival (PFS) and (B) overall survival (OS) do not differ between astrocytomas with <20 total mitoses versus those with 20
or more mitoses present per resection specimen. P values were determined using Cox proportional hazard regression.






















































































model, age 40 was used as a cut-off as this has been used as an
established prognostic marker for patients with lower-grade
diffuse gliomas that guides risk-management and the decision
of watchful waiting versus early treatment strategies (23–28).
While these previously published studies may not be exactly
comparable as our current study, which focuses exclusively on
IDH-mutant astrocytomas (WHO grades II and III), our 40-
year age cut-off allows for some meaningful comparison
across these historical published reports. In addition to using
age 40 years as a cut-off, we also evaluated our Cox model in
relation to median age of our cohort. Replacing the 40-year
cut-off for the median age (<33 vs 33 years) in our Cox
model does not change significance of any parameters exam-
ined and itself is not associated with PFS (HR¼ 0.69, 95%
CI¼ 0.24–1.96, p¼ 0.49) or OS (HR¼ 0.08, 95% CI¼ 0.01–
1.18, p¼ 0.67).
DISCUSSION
Current approaches to distinguish between WHO grade
II and III IDH-mutant diffuse astrocytic gliomas for clinical
risk-stratification have no real prognostic significance (3, 5).
FIGURE 4. Kaplan-Meier progression-free survival (PFS) curves for IDH-mutant astrocytomas stratified by maximum number of
mitoses identified per 10 high-power fields (10 HPF). Mitotic thresholds for each comparison were performed for (A) 1, (B) 2,
(C) 3, (D) 4, (E) 5, and (F) 6 mitotic figures per 10 HPF. P values were determined using Cox proportional hazard regression.






















































































Given that the WHO histological grading scheme is based
solely upon poorly defined “increased mitotic activity”, which
in turn contributes to increased interobserver variability (16),
we sought to determine if quantitative mitotic thresholds in-
formed by clinical outcome could be ascertained for grading
classification of IDH-mutant astrocytomas. If such criteria
could be established, perhaps they could be applied to future
studies and compensate for previously described underper-
formance of histological grading strategies. However, in our
cohort, predictive thresholds could not be established either
for total mitotic activity or for maximum mitotic activity per
10 HPF. It is possible that our threshold cap for total mitotic
activity (20 total mitotic figures per resection specimen) was
too low and that a higher threshold would have provided statis-
tically relevant predictive separation of groups. However, we
evaluated each level of mitotic activity with respect to 10 HPF
and see no significant trend toward separation of groups by
PFS or OS with increasing mitotic activity. We interpret these
FIGURE 5. Kaplan-Meier overall survival (OS) curves for IDH-mutant astrocytomas stratified by maximum number of mitoses
identified per 10 high-power fields (10 HPF). Mitotic thresholds for each comparison were performed for (A) 1, (B) 2, (C) 3, (D)
4, (E) 5, and (F) 6 mitotic figures per 10 HPF. P values were determined using Cox proportional hazard regression.






















































































results to suggest either qualitative or quantitative characteri-
zation of mitotic activity may be the wrong approach to grade
IDH-mutant astrocytomas.
We have previously shown that chromosome 14 loss is a
univariate poor prognostic indicator for PFS in this IDH-mutant
astrocytoma cohort (5). In our current multivariate model, chro-
mosome 14 loss is again identified as an aggressive molecular
marker for PFS, and we have identified unmethylated MGMT
promoter status as another independent correlate of poor PFS.
Consistent with our previous report of CDKN2A homozygous
FIGURE 6. Receiver operating characteristic (ROC) estimation for censored survival data based on mitotic activity in IDH-mutant
astrocytoma. ROC curves for progression-free survival (PFS) based on (A) maximum number of mitotic figures identified per 10
high-power fields (10 HPF) and (B) total mitotic figures. ROC curves for overall survival (OS) based on (C) maximum number of
mitoses identified per 10 HPF and (D) total mitoses present in the pathology specimen.
TABLE. Multivariate Cox Proportional Hazards Model for Our Institutional Cohort of IDH-Mutant Astrocytomas
PFS OS
HR (95% CI) p Value HR (95% CI) p Value
Age: 40 vs <40 years 1.49 (0.50–4.46) 0.48 5.47 (0.43–70.19) 0.19
KPS: 90%–100% vs 70%–80% 1.05 (0.37–3.04) 0.92 0.22 (0.03–1.67) 0.14
EOR: GTR vs STR 0.40 (0.15–1.03) 0.058 0.25 (0.02–3.03) 0.27
Total mitoses: 20 vs <20 1.49 (0.55–4.06) 0.43 5.86 (0.92–37.55) 0.062
MGMT: methylated vs unmethylated 0.25 (0.09–0.69) 0.007 0.38 (0.088–1.64) 0.19
CDKN2A: homozygous deletion vs no homozygous deletion 1.52 (0.44–5.24) 0.51 11.76 (1.98–71.43) 0.007
Chr14: loss vs no loss 8.00 (1.99–32.26) 0.003 2.07 (0.01–423.80) 0.79
HR, hazards ratio; PFS, progression-free survival; OS, overall survival; KPS, Karnofsky performance score; EOR, extent of resection; GTR, gross total resection; STR, subtotal
resection; Chr14, chromosome 14.






















































































deletion as a univariate marker associated with worse OS (5),
we identified CDKN2A homozygous deletion as the most rele-
vant predictor of inferior OS among the investigated tumor fea-
ture in our current multivariate model.
Molecular alterations conferring a more aggressive
(“higher-grade”) clinical behavior are better understood in
IDH-wildtype astrocytic gliomas. IDH-wildtype diffuse astro-
cytomas (WHO grade II) and anaplastic astrocytomas (WHO
grade III) with certain molecular alterations (one or more of
the following: 1—EGFR amplification; 2—TERT promoter
mutation; 3—polysomy chromosome 7 co-occurring with
monosomy chromosome 10) can be considered as “molecular
glioblastoma, WHO grade IV” even in the absence of diagnos-
tic histological features (i.e. necrosis, microvascular prolifera-
tion) traditionally required for the classification of
glioblastoma (29). While the molecular pathways leading to
aneuploidy in glioma are incompletely understood, there is ev-
idence for PDGFA and HOXA5 driving polysomy chromo-
some 7 in IDH-wildtype astrocytic gliomas (30, 31). Within
the designation of histologically defined IDH-wildtype glio-
blastoma, a handful of SCNAs, including CDK4/MDM2 co-
amplification, polysomy chromosome 1, and polysomy chro-
mosome 19, have been demonstrated as having additional
prognostic value beyond glioma histological grading (6, 32).
We know much less about gene and chromosomal level
alterations in IDH-mutant astrocytomas, but it is expected
that, like their IDH-wildtype counterparts, grading is likely to
evolve and incorporate molecular features, specifically
SCNAs, beyond IDHmutational status grading. Emerging evi-
dence suggests that stratifying WHO grade II and III IDH-
mutant astrocytic gliomas by SCNAs, such as CDKN2A dele-
tion, is useful in predicting patient survival and may replace
histological grading (3–6, 8–10). Determining SCNAs may
also be more consistent and reproducible for identifying ag-
gressive IDH-mutant diffuse astrocytic gliomas than current
histopathological grading by mitotic activity alone, thereby re-
ducing the interobserver variability (1, 16, 33, 34) and increas-
ing uniformity in neuropathological diagnosis and clinical
risk-stratification.
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